【摘 要】
：
Objectives To describe hematological adverse events (AE) and explore predictors for dose reduction caused by hematological AE in patients with advanced fibrosis receiving pegylated interferon plus rib
【机 构】
：
Department of Intectious Disease, The Second Xiangya Hospital, Central South University, Changsha, C
【出 处】
：
中华医学会第六次全国艾滋病、病毒性丙型肝炎暨全国热带病学术会议
论文部分内容阅读
Objectives To describe hematological adverse events (AE) and explore predictors for dose reduction caused by hematological AE in patients with advanced fibrosis receiving pegylated interferon plus ribavirin for chronic hepatitis C (CHC) Methods MEDLINE, EMBASE, Web of Science, and The Cochrane library were searched for randomized clinical trials and observational studies reporting hematological AE associated with pegylated interferon plus ribavirin for CHC in patients with stage 3 or 4 fibrosis.Qualified studies were reviewed to extract patients baseline characteristics, disease information, treatment information, and clinical outcomes including incidence and grade of hematologic AE, dose reduction and treatment discontinuation due to hematological AE, and sustained viral response (SVR).
其他文献
Objective The present study was aimed to investigate the immunological pathogenesis of Immune Reconstitution Inflammatory Syndrome (IRIS) in acquired immunodeficiency syndrome (AIDS) patients undergoi
HIV感染者发现率偏低和抗病毒治疗率不足,导致艾滋病疫情仍在不断发展,感染率和死亡率居高不下.由于性传播在全球和我国都已成为最主要的HIV感染途径,在大量研究证据的支持下,WHO近期提出了扩大HIV感染检测率,特别是在HIV感染者的配偶和性伙伴中推广"一起检测和互相披露"的推荐意见.其主要内容就是:配偶/性伙伴无论是已知一方或双方的感染状态或双方都未知,推荐进行HIV感染的"一起检测(test t
Detection of specific antibodies against hepatitis C virus (HCV) is the most widely available test for viral diagnosis and monitoring of HCV infections.However, narrowing the serologic window of anti-
急性丙型肝炎演变成慢性者的比例为60％-85％,甚至更高.20％的慢性丙型肝炎患者逐步演变为肝硬化,因此阻止丙型肝炎慢性化甚为重要.我们收集符合病程在半年以内,有或无乏力、肝区不适等自觉症状,化验HCVRNA阳性.临床明确诊断为急性丙型肝炎的患者资料,分析其流行病学特征、临床症状与疾病转归等情况,把握抗病毒治疗时机.
目的 分析云南省德宏州地区慢性丙型肝炎(CHC)患者的流行病学和临床资料,了解云南缅甸籍华裔慢性丙型肝炎的流行病学特征、临床特点.方法 对2009年1月至2012年12月期间就诊于云南省德宏州人民医院感染科的缅甸籍和中国籍慢性丙型肝炎患者共172例,进行回顾性分析慢性丙型肝炎患者的流行病学特征及临床特点.采用ELASA法检测丙型肝炎病毒(HCV)血清标志物;采用日立全自动生化分析仪检测血清生化学指
目的 价聚乙二醇化干扰素α-2b(佩乐能)联合利巴韦林治疗慢性丙型病毒性肝炎患者的疗效及安全性.方法 9例患者按2∶1随机化分配人组.治疗组20例,依体重不同每周1次皮下注射佩乐能40mcg或50mcg,同时口服利巴韦林750 ～1050mg;对照组9例,每周3次皮下注射干扰素α-2b(甘乐能)3MIU/次,利巴韦林的剂量和服法与治疗组相同.疗程48周,治疗结束后停药观察24周.
替拉瑞韦(Teiaprevir)是由VERTEX公司研发的抗HCV感染的NS3/4A丝蛋白酶抑制剂,商品名Incivek,现已在美国上市.Ⅱ期和Ⅲ期临床试验研究表明,与现行的抗慢性丙肝感染标准治疗方案比较,替拉瑞韦+聚乙二醇干扰素+利巴韦林的三联疗法可大大提高处治患者的持续病毒应答率,且对标准治疗方案难治人种、肝硬化患者、复发患者、部分应答患者和无应答患者均有较好的疗效.并可将疗程由标准治疗方案的
Objective It remains more debated whether amantadine (AMA) and pegylated interferon (Peg-IFN) plus ribavirin (RBV) therapy is more efficacious than Peg-IFN plus RBV therapy in the re-treatmentof chron
Objectives To describe hematological adverse events (AE) and explore predictors for dose reduction caused by hematological AE in patients with advanced fibrosis receiving pegylated interferon plus rib
Background and aims Chronic hepatitis C (CHC) is a progressive fibrotic disease and not an inflammatory hepatitis.IL-22 is found to play a role in fibrogenesis in mice via hepatic stellete cells.Howev